New scrub device aims to cut catheter infections in hospitals
NCT ID NCT06604026
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new cleaning device (BD PosiFlush™ SafeScrub) for needleless connectors on IV lines. The goal was to see if it is safe and helps nurses clean the connectors better than the usual method (using an alcohol pad). 222 adult hospital patients with IV lines took part. The study looked at device-related side effects and how often the connectors were properly cleaned.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
222 people
The number who actually took part.
- Started
-
Oct 2024
- Finished
-
Apr 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Any patient (≥18 years of age) in a high acuity hospital medical or surgical unit regardless of gender, with an eligible in-situ vascular access device and with a needleless access device (NAD). This includes patients who have a current VAD, whether it is newly placed or long-term access as part of their routine medical care. Eligible in-situ vascular access devices are peripheral intravenous catheters (PIVCs), peripherally inserted central catheters (PICCs), central venous catheters (CVCs) and implanted venous access ports. Eligible NADs are stopcocks, Y-sites, and needle-free connectors. 2. Expected to be available until 2 accesses are completed and for any periodic observation upto 15 min after each access. 3. Able and willing to provide informed consent or legal authorized representative (LAR) authorized to give consent on behalf of the participant. Exclusion Criteria: Any patient in whom observation might interfere with medical care or create undue hardship as determined by the patients care team. * Patients under the age of 18. * Patients suffering hypernatremia and fluid retention, when the administration of sodium or chloride could be clinically detrimental as determined by the study investigator. * Patients with a known allergy to any of the followings as determined by the study investigator: * Any of the components or materials of BD PosiFlush™ SafeScrub device or BD PosiFlush™ SP Syringe, or * 0.9% sodium chloride solution * Pregnant or breastfeeding women * Urine pregnancy test will be required for all women of childbearing age who want to participate in the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Crbsi - catheter related bloodstream infection are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical University Vienna
Vienna, Austria
-
Ordensklinikum Linz Elisabethinen
Linz, Upper Austria, 4020, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.